5 Recent Cancer Drug Approvals Patients May Have Missed

The Food and Drug Administration (FDA) has approved several drugs in the cancer space over the last several weeks.

The agency is expected to continue to approve more oncology therapies over the next few months, but in case you missed it, CURE® compiled a list of some of the most recent FDA approvals.

Ukoniq for Certain Previously Treated Patients with Marginal Zone and Follicular Lymphoma

Treatment with Ukoniq (umbralisib) was associated with an overall response rate of 49% in patients with marginal zone lymphoma and 43% in patients with follicular lymphoma. READ MORE.

Tepmetko for Treatment of Adults with Non-Small Lung Cancer Whose Disease Harbors a Certain Mutation

Among patients who had never received prior treatment (69 patients), Tepmetko (tepotinib) induced an overall response rate of 43% and a median duration of response of 10.8 months. READ MORE.

Breyanzi to Treat Certain Types of Large B-Cell Lymphoma

Among more than 250 adults with relapsed/refractory large B-cell lymphoma, treatment with Breyanzi (lisocabtagene maraleucel) induced a complete remission rate of 54%. READ MORE.

Front-Line Libtayo for Advanced Non-Small Cell Lung Cancer Subset

Treatment with Libtayo (cemiplimab-rwlc) reduced the risk of death by 32% compared to chemotherapy in patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression. An additional analysis of 563 patients with proven PD-L1 expression of 50% or higher found that Libtayo reduced the risk of death by 43% compared to chemotherapy. READ MORE.

Cosela to Reduce Bone Marrow Suppression Caused by Chemo in Certain Patients with Lung Cancer

Patients who received Cosela (trilaciclib) had a lower risk of severe neutropenia compared to placebo in all three trials. Those who had severe neutropenia and received Cosela, had it for a shorter amount of time than those who received placebo. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.